Marc Yeste, Phd
Director, Translational Research
Pharma
Ability Pharmaceuticals S.L
Spain
Biography
Marc obtained a BSc degree, a MSc degree in experimental biochemistry and a PhD degree in molecular biology from the University of Barcelona. During his PhD degree he investigated the apoptotic pathways involved in neuronal apoptosis using neurodegeneration models. Afterwards he moved to London to work as a postdoctoral research associate at Barts Cancer Institute (Queen Mary University of London), where he started his career in cancer research. He studied the molecular mechanisms involved in the development of prostate and testicular cancers and also investigated the potential use of an antibody-drug conjugate to treat testicular cancers in collaboration with Takeda Oncology. Then he moved to industry to work as a principal scientist at Vasgen Ltd., where he developed monoclonal antibodies to be used as inhibitors of metalloproteinases activity and investigated its potential therapeutic use to treat cancer and neovascular ocular diseases. Marc has published 20 papers in peer-reviewed journals and presented his work in international scientific meetings. In 2016 he joined Ability Pharmaceuticals, SL as translational research director.
Research Interest
neuronal apoptosis using neurodegeneration models.
